WASHINGTON—Gilead Sciences Inc. said Monday that its experimental anti-coronavirus drug remdesivir will be supplied to the governments of developed countries at what it sees as an affordable price of US$2,340 (3.2 million kyats) per patient for a typical five-day treatment course.
The US biopharmaceutical company has been donating worldwide, including to Japan, doses of the antiviral drug that has demonstrated patient improvement in clinical trials for the disease triggered by the novel coronavirus. But it had not been clear what the price tag of the drug would be after the donations ended.
Read more.
You may also like these stories:
Japan Approves US-Made Drug Remdesivir to Treat COVID-19
Frontline Health-Care Workers in Japan Face Discrimination Due to Virus Fears
